Integra Lifesciences Holdings (IART) Accounts Payables (2009 - 2026)

Integra Lifesciences Holdings (IART) has 18 years of Accounts Payables data on file, last reported at $87.9 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables fell 3.67% year-over-year to $87.9 million; the trailing twelve-month figure through Mar 2026 stood at $87.9 million (down 3.67% YoY), and the FY2025 full-year result was $95.7 million, up 16.03% from the prior year.
• Accounts Payables eased to $87.9 million in Q1 2026, from $95.7 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $112.8 million in Q1 2023 to a low of $69.5 million in Q2 2022.
• A 5-year average of $91.8 million and a median of $92.3 million in 2023 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables jumped 65.11% in 2022 and retreated 16.98% in 2024, its largest moves.
• Tracing IART's Accounts Payables over 5 years: stood at $102.1 million in 2022, then decreased by 9.57% to $92.3 million in 2023, then fell by 10.64% to $82.5 million in 2024, then gained by 16.03% to $95.7 million in 2025, then slipped by 8.13% to $87.9 million in 2026.
• Business Quant data shows IART's Accounts Payables at $87.9 million in Q1 2026, $95.7 million in Q4 2025, and $92.3 million in Q3 2025.